Silence Therapeutics (SLN) Operating Expenses (2020 - 2026)

Silence Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 13245.45% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $77.3 million (up 373.42% YoY), while the FY2025 annual figure was $91.4 million, up 584.74% from the prior year.
• Operating Expenses came in at $16.1 million for Q1 2026 at Silence Therapeutics, down from $31.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $143.1 million in Q4 2023 to a low of -$27.2 million in Q3 2024.
• A 5-year average of $11.0 million and a median of -$3.5 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses tumbled 98.16% in 2024 and jumped 13245.45% in 2026, its largest moves.
• Silence Therapeutics' Operating Expenses stood at $115.6 million in 2022, then gained by 23.76% to $143.1 million in 2023, then sank by 98.16% to $2.6 million in 2024, then surged by 1090.71% to $31.4 million in 2025, then plunged by 48.59% to $16.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $16.1 million, $31.4 million, and $26.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison